Tag: Polyneuropathy

Explore our medication guides and pharmacology articles within this category.

What is the difference between Onpattro and AMVUTTRA?

Oct 9, 2025 •

5 min read

Hereditary transthyretin-mediated (hATTR) amyloidosis affects an estimated 50,000 people worldwide [1.5.3, 1.5.4]. This article explores what is the difference between Onpattro and AMVUTTRA, two RNA interference (RNAi) therapies used to treat its symptoms.

What Is Onpattro? An RNAi Therapy for hATTR Amyloidosis

Oct 7, 2025 •

4 min read

As the first FDA-approved small interfering RNA (siRNA) therapy, Onpattro (patisiran) represents a significant advance in treating hereditary transthyretin-mediated (hATTR) amyloidosis. This groundbreaking medication uses a unique gene-silencing mechanism to address the root cause of the disease, rather than just managing its symptoms.